Showing results (251-260 of 496) with videos related to
Sort By:
Pageof 50
Pharmacoepidemiology and Drug Safety|October 13, 2024
Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded IndicationsAnjali D Deshmukh, Aaron S Kesselheim, Theodore Tsacogianis, et al.Health Affairs (Project Hope)|February 4, 2015
Repairing the broken market for antibiotic innovationKevin Outterson, John H Powers, Gregory W Daniel, et al.American Journal of Infection Control|April 23, 2021
The impact of infections on reimbursement in 92 US hospitals, 2015-2018Laura Puzniak, Vikas Gupta, Kalvin C Yu, et al.Heart Rhythm|July 24, 2010
Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessmentDaniel B Kramer, Aaron S Kesselheim, Dan W Brock, et al.JAMA Network Open|May 4, 2021
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket CostsBenjamin N Rome, William B Feldman, Rishi J Desai, et al.Health Affairs (Project Hope)|June 2, 2020
Estimating The Cost Of Delayed Generic Drug Entry To MedicaidChintan V Dave, Michael S Sinha, Reed F Beall, et al.Clinical Pharmacology and Therapeutics|March 16, 2022
Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi PanelSanket S Dhruva, Jonathan J Darrow, Aaron S Kesselheim, et al.The Oncologist|June 14, 2025
Medicare spending and use of subcutaneous biologic formulations with hyaluronidaseJohn Kim, Aaron S Kesselheim, Edward R Scheffer Cliff, et al.JCO Oncology Practice|November 7, 2025
Pricing Trends and Overlapping Indications of Checkpoint Inhibitors for Cancer TreatmentJeddeo M Paul, Aaron P Mitchell, Aaron S Kesselheim, et al.Journal of General Internal Medicine|February 6, 2024
Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer PharmaciesHussain S Lalani, Frazer A Tessema, Aaron S Kesselheim, et al.Pageof 50